All In Biotech

Drug Trial Radar · NCT05913752

A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Subjects

A Phase I/II Single and Multiple Dose Tolerability, Safety and Pharmacokinetic Study of CMND-100 in Healthy Volunteers and Subjects With Alcohol Use Disorder (AUD)

Last checked: Nov 19, 2026Latest source record: Mar 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

84

Planned (sponsor's estimate)

Start

Apr 30, 2025

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Clearmind Medicine Inc.Industry
Sponsor type
Industry
First posted
Jun 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this study is to find the tolerable dose and characterize the safety and pharmacokinetics/ pharmacodynamics (PK/PD) of single and repeated dose of CMND-100 in Healthy Volunteers (HV) and Subjects with Alcohol Use Disorder (AUD). The secondary objective of this study is to preliminarily evaluate the efficacy of CMND-100 in reduction of drinking patterns and craving in subjects with moderate to severe AUD.

Conditions

  • Alcohol Use Disorder

Interventions

  • CMND-100Drug

    The investigational product CMND-100 consists of gelatin capsules, each containing the active ingredient (either 20 or 60 mg) 5-methoxy-2-aminoindane (MEAI) and excipients (stabilizers). MEAI is a psychoactive compound of the aminoindane class

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety as Adverse Events ProfileTime frame: up to 31 days
  2. TmaxTime frame: up to 31 days
  3. CmaxTime frame: up to 31 days
  4. AUC0-∞Time frame: up to 31 days
  5. t1/2Time frame: up to 31 days
  6. ClTime frame: up to 31 days
  7. VdTime frame: up to 31 days

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Connecticut Mental Health Center

    New Haven, Connecticut · Recruiting

  • Johns Hopkins Bayview Medical Center

    Baltimore, Maryland · Recruiting

  • Hadassah Medical Center

    Jerusalem, Israel · Recruiting

  • Tel-Aviv Sourasky Medical Center (TASMC)

    Tel Aviv, Israel · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.